Hematologically important mutations: X-linked chronic granulomatous disease (third update) - PubMed (original) (raw)

Review

. 2010 Oct 15;45(3):246-65.

doi: 10.1016/j.bcmd.2010.07.012. Epub 2010 Aug 21.

Douglas B Kuhns, Anne Maddalena, Joachim Roesler, Juan Alvaro Lopez, Tadashi Ariga, Tadej Avcin, Martin de Boer, Jacinta Bustamante, Antonio Condino-Neto, Gigliola Di Matteo, Jianxin He, Harry R Hill, Steven M Holland, Caroline Kannengiesser, M Yavuz Köker, Irina Kondratenko, Karin van Leeuwen, Harry L Malech, László Marodi, Hiroyuki Nunoi, Marie-José Stasia, Anna Maria Ventura, Carl T Witwer, Baruch Wolach, John I Gallin

Affiliations

• PMID: 20729109
• PMCID: PMC4360070
• DOI: 10.1016/j.bcmd.2010.07.012

Review

Hematologically important mutations: X-linked chronic granulomatous disease (third update)

Dirk Roos et al. Blood Cells Mol Dis. 2010.

Abstract

Chronic granulomatous disease (CGD) is an immunodeficiency disorder affecting about 1 in 250,000 individuals. The disease is caused by a lack of superoxide production by the leukocyte enzyme NADPH oxidase. Superoxide is used to kill phagocytosed micro-organisms in neutrophils, eosinophils, monocytes and macrophages. The leukocyte NADPH oxidase is composed of five subunits, of which the enzymatic component is gp91-phox, also called Nox2. This protein is encoded by the CYBB gene on the X chromosome. Mutations in this gene are found in about 70% of all CGD patients. This article lists all mutations identified in CYBB in the X-linked form of CGD. Moreover, apparently benign polymorphisms in CYBB are also given, which should facilitate the recognition of future disease-causing mutations.

Copyright © 2010 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Similar articles

• Hematologically important mutations: X-linked chronic granulomatous disease (fourth update).
  Roos D, van Leeuwen K, Hsu AP, Priel DL, Begtrup A, Brandon R, Stasia MJ, Bakri FG, Köker N, Köker MY, Madkaika M, de Boer M, Garcia-Morato MB, Shephard JLV, Roesler J, Kanegane H, Kawai T, Di Matteo G, Shahrooei M, Bustamante J, Rawat A, Vignesh P, Mortaz E, Fayezi A, Cagdas D, Tezcan I, Kitcharoensakkul M, Dinauer MC, Meyts I, Wolach B, Condino-Neto A, Zerbe CS, Holland SM, Malech HL, Gallin JI, Kuhns DB. Roos D, et al. Blood Cells Mol Dis. 2021 Sep;90:102587. doi: 10.1016/j.bcmd.2021.102587. Epub 2021 Jun 2. Blood Cells Mol Dis. 2021. PMID: 34175765 Review.
• Hematologically important mutations: The autosomal forms of chronic granulomatous disease (third update).
  Roos D, van Leeuwen K, Hsu AP, Priel DL, Begtrup A, Brandon R, Rawat A, Vignesh P, Madkaikar M, Stasia MJ, Bakri FG, de Boer M, Roesler J, Köker N, Köker MY, Jakobsen M, Bustamante J, Garcia-Morato MB, Shephard JLV, Cagdas D, Tezcan I, Sherkat R, Mortaz E, Fayezi A, Shahrooei M, Wolach B, Blancas-Galicia L, Kanegane H, Kawai T, Condino-Neto A, Vihinen M, Zerbe CS, Holland SM, Malech HL, Gallin JI, Kuhns DB. Roos D, et al. Blood Cells Mol Dis. 2021 Dec;92:102596. doi: 10.1016/j.bcmd.2021.102596. Epub 2021 Jul 28. Blood Cells Mol Dis. 2021. PMID: 34547651
• Two X-linked chronic granulomatous disease patients with unusual NADPH oxidase properties.
  Wolach B, Broides A, Zeeli T, Gavrieli R, de Boer M, van Leeuwen K, Levy J, Roos D. Wolach B, et al. J Clin Immunol. 2011 Aug;31(4):560-6. doi: 10.1007/s10875-011-9537-3. Epub 2011 May 21. J Clin Immunol. 2011. PMID: 21604087
• Point mutations in the promoter region of the CYBB gene leading to mild chronic granulomatous disease.
  Weening RS, De Boer M, Kuijpers TW, Neefjes VM, Hack WW, Roos D. Weening RS, et al. Clin Exp Immunol. 2000 Dec;122(3):410-7. doi: 10.1046/j.1365-2249.2000.01405.x. Clin Exp Immunol. 2000. PMID: 11122248 Free PMC article.
• Hematologically important mutations: the autosomal recessive forms of chronic granulomatous disease (second update).
  Roos D, Kuhns DB, Maddalena A, Bustamante J, Kannengiesser C, de Boer M, van Leeuwen K, Köker MY, Wolach B, Roesler J, Malech HL, Holland SM, Gallin JI, Stasia MJ. Roos D, et al. Blood Cells Mol Dis. 2010 Apr 15;44(4):291-9. doi: 10.1016/j.bcmd.2010.01.009. Epub 2010 Feb 18. Blood Cells Mol Dis. 2010. PMID: 20167518 Free PMC article. Review.

Cited by

• Genetic and Clinical Profiles of Disseminated Bacillus Calmette-Guérin Disease and Chronic Granulomatous Disease in China.
  Li T, Zhou X, Ling Y, Jiang N, Ai J, Wu J, Chen J, Chen L, Qian X, Liu X, Xi X, Xia L, Fan X, Lu S, Zhang WH. Li T, et al. Front Immunol. 2019 Jan 29;10:73. doi: 10.3389/fimmu.2019.00073. eCollection 2019. Front Immunol. 2019. PMID: 30761141 Free PMC article.
• Precise somatic genome editing for treatment of inborn errors of immunity.
  Meng Q, Sun H, Liu J. Meng Q, et al. Front Immunol. 2022 Aug 26;13:960348. doi: 10.3389/fimmu.2022.960348. eCollection 2022. Front Immunol. 2022. PMID: 36091069 Free PMC article. Review.
• Rare duplication or deletion of exons 6, 7 and 8 in CYBB leading to X-linked chronic granulomatous disease in two patients from different families.
  Stasia MJ, van Leeuwen K, de Boer M, Martel C, Mollin M, Thuret I, Michel G, Hanson C, Augustine NH, Coutton C, Satre V, Wittwer CT, Hill H, Roos D. Stasia MJ, et al. J Clin Immunol. 2012 Aug;32(4):653-62. doi: 10.1007/s10875-012-9667-2. Epub 2012 Mar 2. J Clin Immunol. 2012. PMID: 22382877
• P67-phox (NCF2) lacking exons 11 and 12 is functionally active and leads to an extremely late diagnosis of chronic granulomatous disease (CGD).
  Roesler J, Segerer F, Morbach H, Kleinert S, Thieme S, Rösen-Wolff A, Liese JG. Roesler J, et al. PLoS One. 2012;7(4):e34296. doi: 10.1371/journal.pone.0034296. Epub 2012 Apr 13. PLoS One. 2012. PMID: 22514628 Free PMC article.
• Geographic Variability and Pathogen-Specific Considerations in the Diagnosis and Management of Chronic Granulomatous Disease.
  Prince BT, Thielen BK, Williams KW, Kellner ES, Arnold DE, Cosme-Blanco W, Redmond MT, Hartog NL, Chong HJ, Holland SM. Prince BT, et al. Pediatric Health Med Ther. 2020 Jul 22;11:257-268. doi: 10.2147/PHMT.S254253. eCollection 2020. Pediatric Health Med Ther. 2020. PMID: 32801991 Free PMC article. Review.

References

1. 1. Heyworth PG, Curnutte JT, Rae J, Noack D, Roos D, van Koppen E, Cross AR. Hematologically important mutations: X-linked chronic granulomatous disease (second update) Blood Cells Mol. Dis. 2001;27:16–26. - PubMed
2. 1. Roos D, Kuijpers TW, Curnutte JT. Chronic granulomatous disease. In: Ochs HD, Smith CIE, Puck JM, editors. Primary immunodeficiency diseases, a molecular and genetic approach. 2nd edition. New York: Oxford University Press; 2007. pp. 525–549.
3. 1. Stasia MJ, Li XJ. Genetics and immunopathology of chronic granulomatous disease. Semin Immunopathol. 2008;30:209–235. - PubMed
4. 1. Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, Rossi P, Gattorno M, Rabusin M, Azzari C, Dellepiane RM, Pietrogrande MC, Trizzino A, Di Bartolomeo P, Martino S, Carpino L, Cossu F, Locatelli F, Maccario R, Pierani P, Putti MC, Stabile A, Notarangelo LD, Ugazio AG, Plebani A, De Mattia D. Clinical features, long-term follow-up and outcome of a large cohort of patients with chronic granulomatous disease: an Italian multicenter study. Clin. Immunol. 2008;126:155–164. - PubMed
5. 1. Jones LB, McGrogan P, Flood TJ, Gennery AR, Morton L, Thrasher A, Goldblatt D, Parker L, Cant AJ. Chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin. Exp. Immunol. 2008;152:211–218. - PMC - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal